Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Preferred Stock Liabilities (2024)

Caris Life Sciences has reported Preferred Stock Liabilities over the past 1 years, most recently at $2.2 billion for Q4 2024.

  • Quarterly results put Preferred Stock Liabilities at $2.2 billion for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $2.2 billion (changed N/A YoY), and the annual figure for FY2024 was $2.2 billion, up 4.53%.
  • Preferred Stock Liabilities for Q4 2024 was $2.2 billion at Caris Life Sciences, up from $2.2 billion in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CAI hit a ceiling of $2.2 billion in Q4 2024 and a floor of $2.2 billion in Q2 2024.